Detection of Suspected Paper Mill Publications in Cancer Research Using Machine Learning
January 30, 2026
Brand Name :
AdreView
Synonyms :
iobenguane I-123
Class :
Diagnostic Imaging Agents
Dosage Forms & Strengths
Solution
2 millicurie/ml
Gamma Scintigraphy
Administer dose of 10 millicurie intravenously
Begin whole body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration
Congestive Heart Failure (CHF)
Administer dose of 10 millicurie intravenously
Begin anterior planar imaging of the chest at 4 hours (plus or minus 10 minutes) after administration
Administration
Administer intravenous infusion over 1 to 2 minutes, then flush with 0.9% sodium chloride to guarantee of complete administration of the dose
Dosage Forms & Strengths
Solution
2 millicurie/ml
Gamma Scintigraphy
Start full body planar scintigraphy imaging 24 hours (plus or minus 6 hours) after administration
Congestive Heart Failure (CHF)
Gamma Scintigraphy
Start anterior planar imaging of the chest at 4 hours (plus or minus 10 minutes) after administration
Neonates <1 month: Safety and efficacy not determined
<16 years old and ≥70 kg: 10 millicurie
Children ≥16 years: follow as per adult dosing instructions
Administration
Administer intravenous infusion over 1 to 2 minutes, then flush with 0.9% sodium chloride to guarantee of complete administration of the dose
Refer to adult dosing
Actions and Spectrum
iobenguane I-123 is a radiolabelled analog of norepinephrine and acts as a radiotracer. It works by binding to norepinephrine transporters (NETs) on the surface of certain cells, particularly of the adrenal medulla and sympathetic nervous system.
Frequency not defined
Dizziness
Injection site hemorrhage
Flushing
Pruritus
Rash
Post marketing Reports
Hypersensitivity
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
Pregnancy consideration:
Pregnancy category: N/A
Lactation: It is present in human breast milk
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
iobenguane I-123 is a synthetic analog of norepinephrine, a neurotransmitter involved in the sympathetic nervous systems signaling.
Radiotracers are compounds that emit radiation that can be detected externally using specialized imaging equipment.
Pharmacodynamics
iobenguane I-123 circulates in the bloodstream and is actively taken up by cells expressing NETs. In the adrenal medulla, it accumulates in specialized cells called chromaffin cells.
Pharmacokinetics
Absorption
iobenguane I-123 administered intravenously, directly into the vein.
Distribution
iobenguane I-123 distributes throughout the body.
Metabolism
iobenguane I-123 is not significantly metabolized within the body.
Elimination and excretion
iobenguane I-123 is excreted primarily through the kidneys. The half-life of drug is around 13.2 hours.
Administration
iobenguane I-123 is administered as intravenous injection directly into a bloodstream.
Patient information leaflet
Generic Name: iobenguane I-123
Why do we use iobenguane I-123?
iobenguane I-123 is used for the imaging and evaluation of neuroendocrine tumors, particularly pheochromocytoma and paraganglioma. iobenguane I-123 is used for the evaluation of cardiac sympathetic innervation in patients with heart failure or certain arrhythmias.